John D. Wagstaff
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 0.1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 76
- Cancer Immunotherapy and Biomarkers 29
- CAR-T cell therapy research 12
-
- Renal cell carcinoma treatment 22
- Prostate Cancer Treatment and Research 12
- Co-authors
- Cezary A. Szczylik (4 shared papers)Ian D. Davis (3 shared papers)Oleg A. Gladkov (3 shared papers)Pamela Salman (3 shared papers)Jozef Mardiak (3 shared papers)Carlos H. Barrios (3 shared papers)Lauren A. McCann (3 shared papers)Robert E. Hawkins (3 shared papers)
- Journals
- Annals of Oncology (22 papers)European Journal of Cancer (14 papers)British Journal of Cancer (12 papers)New England Journal of Medicine (8 papers)Journal of Clinical Oncology (7 papers)
- Partner nations
- United KingdomNetherlandsUnited States
In The Last Decade
John D. Wagstaff
222 papers receiving 35.1k citations
John D. Wagstaff's Hit Papers
Peers
Comparison fields: 5 of 145
- Oncology 18.0k
- Immunology 8.1k
- Pulmonary and Respiratory Medicine 10.2k
- Cancer Research 3.7k
- Molecular Biology 8.2k
Countries citing papers authored by John D. Wagstaff
This map shows the geographic impact of John D. Wagstaff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John D. Wagstaff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John D. Wagstaff more than expected).
Fields of papers citing papers by John D. Wagstaff
This network shows the impact of papers produced by John D. Wagstaff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John D. Wagstaff. The network helps show where John D. Wagstaff may publish in the future.
Co-authors
The 25 scholars most cited alongside John D. Wagstaff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 226 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma Hit paper breakdown → | 2015 | 6916 |
| 2 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 4815 |
| 3 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2017 | 4597 |
| 4 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2019 | 2848 |
| 5 | Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial Hit paper breakdown → | 2010 | 2078 |
| 6 | Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Hit paper breakdown → | 2015 | 1540 |
| 7 | Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy Hit paper breakdown → | 2017 | 1350 |
| 8 | Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial Hit paper breakdown → | 2018 | 1153 |
| 9 | Therapeutic vaccines for cancer: an overview of clinical trials Hit paper breakdown → | 2014 | 664 |
| 10 | Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma Hit paper breakdown → | 2022 | 492 |
| 11 | A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update Hit paper breakdown → | 2013 | 382 |
| 12 | Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib Hit paper breakdown → | 2018 | 367 |
| 13 | Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial Hit paper breakdown → | 2020 | 353 |
| 14 | Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial Hit paper breakdown → | 2019 | 313 |
| 15 | 2006 | 288 | |
| 16 | Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2024 | 285 |
| 17 | 2020 | 247 | |
| 18 | Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. | 2003 | 242 |
| 19 | Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Hit paper breakdown → | 2022 | 239 |
| 20 | 2006 | 230 |
About John D. Wagstaff
John D. Wagstaff is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Cancer Research and Molecular Biology, having authored 226 papers that have together received 35.9k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (29 papers), Renal cell carcinoma treatment (22 papers), Lymphoma Diagnosis and Treatment (19 papers), Immunotherapy and Immune Responses (15 papers), Genetic Syndromes and Imprinting (14 papers), Prostate Cancer Treatment and Research (12 papers), CAR-T cell therapy research (12 papers) and Chronic Lymphocytic Leukemia Research (12 papers). The work is most often cited by research in Oncology (18.0k citations), Immunology (8.1k citations), Pulmonary and Respiratory Medicine (10.2k citations), Cancer Research (3.7k citations) and Molecular Biology (8.2k citations). John D. Wagstaff has collaborated with scholars based in United Kingdom, Netherlands and United States. Frequent co-authors include Cezary A. Szczylik, Ian D. Davis, Oleg A. Gladkov, Pamela Salman, Jozef Mardiak, Carlos H. Barrios, Lauren A. McCann, Robert E. Hawkins, Cora Nanette Sternberg and Eunsik Lee. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, British Journal of Cancer, New England Journal of Medicine and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.